What is the appropriate ICD‑10 code for a patient with hypothyroidism who has a low thyroid‑stimulating hormone (TSH) level due to an excessive dose of levothyroxine (synthetic thyroxine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

ICD-10 Coding for Iatrogenic Hyperthyroidism Due to Excessive Levothyroxine

The appropriate ICD-10 code for a patient with hypothyroidism who has developed a low TSH due to excessive levothyroxine dosing is E06.4 (Drug-induced thyroiditis) or more specifically E05.90 (Thyrotoxicosis, unspecified) combined with a secondary code for adverse effect of thyroid hormones and substitutes, T38.1X5A (Adverse effect of thyroid hormones and substitutes, initial encounter).

Understanding the Clinical Scenario

This represents iatrogenic thyrotoxicosis or overtreatment with levothyroxine. The FDA label clearly identifies this as "overdosage" when signs and symptoms of hyperthyroidism occur 1. The clinical guidelines emphasize that overtreatment occurs in approximately 20% of patients on thyroid hormone replacement and carries significant risks including cardiovascular complications, accelerated bone loss, and affective disturbances 2.

Coding Approach

Primary Diagnosis Options:

  • E05.90 (Thyrotoxicosis, unspecified) - This captures the biochemical state of excess thyroid hormone
  • E06.4 (Drug-induced thyroiditis) - This may be appropriate if there's evidence of thyroid inflammation
  • E03.9 (Hypothyroidism, unspecified) - The underlying condition being treated

Essential Secondary Code:

  • T38.1X5A (Adverse effect of thyroid hormones and substitutes, initial encounter) - This is critical as it identifies the medication as the cause and classifies it as an adverse effect rather than poisoning or underdosing

Additional Considerations:

The "X" in T38.1X5A requires a placeholder for the 6th character position. The 7th character "A" indicates initial encounter; use "D" for subsequent encounters.

Clinical Context from Guidelines

The guidelines stress that levothyroxine has a narrow therapeutic index 1. Overtreatment consequences include:

  • Cardiovascular effects: Increased heart rate, cardiac wall thickness, arrhythmias (especially atrial fibrillation in elderly) 1
  • Skeletal effects: Accelerated bone loss, particularly in postmenopausal women 2
  • Metabolic complications: Accelerated osteoporosis with long-term excessive replacement 3

Important Coding Pitfalls to Avoid

  1. Do not use poisoning codes (T38.1X1A) - This scenario represents therapeutic use at an incorrect dose, not intentional or accidental poisoning
  2. Do not use underdosing codes (T38.1X6A) - This is the opposite problem
  3. Always include both the manifestation (thyrotoxicosis) and the drug-related code - This provides complete documentation of the clinical situation

Documentation Requirements

For proper coding, the medical record should document:

  • Current TSH level (suppressed/low)
  • Current levothyroxine dose
  • Evidence that the dose is excessive for the patient
  • Any clinical manifestations of thyrotoxicosis (tachycardia, weight loss, tremor, etc.)
  • The underlying hypothyroidism diagnosis

The FDA label specifies that symptoms of overdosage include those of hyperthyroidism, and may also include confusion and disorientation, with more severe cases potentially involving cerebral embolism, shock, or coma 1. However, symptoms may not appear until several days after ingestion.

Management Implications

According to the FDA label, management involves reducing or temporarily discontinuing levothyroxine 1. The guidelines recommend monitoring TSH within 4-8 weeks after dose adjustments 2, and emphasize that the goal is to maintain TSH within the normal reference range while avoiding both under- and overtreatment 2.

References

2
Guideline

clinical practice guidelines for hypothyroidism in adults: cosponsored by the american association of clinical endocrinologists and the american thyroid association.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2012

3
Research

Excessive thyroid hormone replacement therapy.

The Journal of the American Board of Family Practice, 1995

Related Questions

How should the dose of levothyroxine (Unithroid) 75 µg be adjusted for a patient with a thyroid‑stimulating hormone level of 5.1 mIU/L?
What initial levothyroxine dose should be started in a newly diagnosed hypothyroid pregnant woman based on her pre‑pregnancy weight?
Can I switch her from levothyroxine 100 µg daily to Armour thyroid (desiccated thyroid) and what initial dose should be used?
In an 87‑year‑old patient taking levothyroxine 88 µg daily with a thyroid‑stimulating hormone (TSH) of 50.3 mIU/L, triiodothyronine (T3) of 0.66, and thyroxine (T4) of 3.4, how should the levothyroxine dose be adjusted?
How should the levothyroxine dose be adjusted for a 56-year-old woman with hypothyroidism taking 75 µg Synthroid (levothyroxine) who has a TSH of 29.8 mIU/L?
Can memantine cause unilateral (left-sided) weakness?
Is a Medrol (methylprednisolone) dose pack indicated for neck pain caused by muscle tightness?
What gastric side effects can amitriptyline cause and how should they be managed?
In a patient with a proximal humerus fracture, is a shoulder X‑ray the preferred initial imaging study?
In colorectal cancer, which tumor‑informed circulating tumor DNA minimal residual disease assay—Natera Signatera or Tempus xM (NeXT Personal Dx)—offers superior clinical validation, sensitivity, specificity, published evidence, clinical utility, performance, regulatory status, laboratory location, and year of introduction, and which would you personally select for optimal patient management?
What are the recommended AUC‑guided dosing regimens for antibiotics (e.g., vancomycin, aminoglycosides, fluoroquinolones, daptomycin) in a typical adult with normal renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.